Guardant Health Inc. (NASDAQ:GH) went down by -0.49% from its latest closing price compared to the recent 1-year high of $181.07. The company’s stock price has collected -2.67% of loss in the last five trading sessions. Press Release reported on 06/08/21 that Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer
Is It Worth Investing in Guardant Health Inc. (NASDAQ :GH) Right Now?
Opinions of the stock are interesting as 14 analysts out of 15 who provided ratings for Guardant Health Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $171.31, which is $58.69 above the current price. GH currently public float of 96.13M and currently shorts hold a 4.37% ratio of that float. Today, the average trading volume of GH was 909.58K shares.
GH’s Market Performance
GH stocks went down by -2.67% for the week, with a monthly drop of -6.21% and a quarterly performance of -16.44%, while its annual performance rate touched 42.42%. The volatility ratio for the week stands at 3.60% while the volatility levels for the past 30 days are set at 4.34% for Guardant Health Inc.. The simple moving average for the period of the last 20 days is -3.40% for GH stocks with a simple moving average of -11.79% for the last 200 days.
Analysts’ Opinion of GH
Many brokerage firms have already submitted their reports for GH stocks, with Goldman repeating the rating for GH by listing it as a “Buy.” The predicted price for GH in the upcoming period, according to Goldman is $160 based on the research report published on June 03rd of the current year 2021.
Wells Fargo, on the other hand, stated in their research note that they expect to see GH reach a price target of $145. The rating they have provided for GH stocks is “Overweight” according to the report published on May 25th, 2021.
Stifel gave a rating of “Buy” to GH, setting the target price at $175 in the report published on January 11th of the current year.
GH Trading at -17.90% from the 50-Day Moving Average
After a stumble in the market that brought GH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.92% of loss for the given period.
Volatility was left at 4.34%, however, over the last 30 days, the volatility rate increased by 3.60%, as shares sank -4.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.55% lower at present.
During the last 5 trading sessions, GH fell by -2.67%, which changed the moving average for the period of 200-days by +22.19% in comparison to the 20-day moving average, which settled at $117.94. In addition, Guardant Health Inc. saw -11.37% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at GH starting from MERESMAN STANLEY J, who sale 4,934 shares at the price of $133.01 back on May 10. After this action, MERESMAN STANLEY J now owns 4,059 shares of Guardant Health Inc., valued at $656,271 using the latest closing price.
Kaul Samir, the Director of Guardant Health Inc., sale 5,000 shares at $142.85 during a trade that took place back on May 05, which means that Kaul Samir is holding 14,943 shares at $714,242 based on the most recent closing price.
Stock Fundamentals for GH
Current profitability levels for the company are sitting at:
- -85.53 for the present operating margin
- +67.73 for the gross margin
The net margin for Guardant Health Inc. stands at -88.51. The total capital return value is set at -15.80, while invested capital returns managed to touch -17.00. Equity return is now at value -30.90, with -18.80 for asset returns.
Based on Guardant Health Inc. (GH), the company’s capital structure generated 65.81 points at debt to equity in total, while total debt to capital is 39.69. Total debt to assets is 37.61, with long-term debt to equity ratio resting at 65.30. Finally, the long-term debt to capital ratio is 39.38.
When we switch over and look at the enterprise to sales, we see a ratio of 40.75, with the company’s debt to enterprise value settled at 0.07. The receivables turnover for the company is 5.66 and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 28.27.